Cytochrome P450 (P450) plays a key role in the oxidative metabolism of drugs and xenobiotics, many of which are lipophilic and to be excreted they should be transformed into more polar water soluble molecules by the system of hepatic mono-oxygenases ([Lim and Lu, 1998](#bib17){ref-type="other"}).

P450 can be influenced by a number of exogenous and endogenous factors ([Whitlock and Denison, 1995](#bib31){ref-type="other"}) and its induction and inhibition is of the utmost interest in carcinogenesis ([Toussaint *et al*, 1993](#bib29){ref-type="other"}).

We have earlier proposed a mechanism for the onset of hepatocarcinogenesis involving an activating status of the whole liver which reflected an important and sustained increase in P450 levels, leading to biochemical aberrations in haem metabolism which in turn would lead to the tumorigenic process ([Gerez *et al*, 1997](#bib10){ref-type="other"}). We have also suggested that reactive oxygen species (ROS), produced during carcinogenesis chemically induced by p-dimethylaminoazobenzene (DAB), would be involved in the generation of hepatic lesions ([Gerez *et al*, 1998a](#bib11){ref-type="other"},[b](#bib12){ref-type="other"}) and the so triggered peroxidative damage would be implicated in the initiation step of hepatocarcinogenesis.

The development of cancer is a dynamic process of de-regulation of gene function. Accumulation of damage alters gene function and clonal expansion of mutated cells ([Cerutti, 1994](#bib3){ref-type="other"}). During drug metabolism, generated reactive oxygen species (ROS) play a key role in several stages of carcinogenesis ([Halliwell, 1999](#bib14){ref-type="other"}; [Caballero *et al*, 2001](#bib2){ref-type="other"}).

Cimetidine (CIM) is a H~2~-histamine receptor antagonist clinically used in the treatment of peptic ulcers and other gastric acid-related disorders ([Chang *et al*, 1992a](#bib5){ref-type="other"}). It inhibits hepatic mixed-function oxidase activity ([Baird *et al*, 1987](#bib1){ref-type="other"}) and it appears that CIM is a more potent inhibitor of hepatic P450 when administered *in vivo* than when it is added to microsomes *in vitro* ([Chang *et al*, 1992b](#bib6){ref-type="other"}).

The presence of a high affinity binding site for CIM on P450 in liver microsomes, with both the imidazole and cyano positions of CIM interacting with the hemin iron is well documented. Ranitidine, a structurally dissimilar H~2~-histamine antagonist, not inhibiting hepatic mixed-function oxidases, has not a binding site on P450, suggesting therefore that CIM would alter the oxidative metabolism of some compounds by having a direct inhibitory effect on P450. If CIM exerts a significant general effect upon haem biosynthetic and/or degradative pathway, we would expect these effects to be manifest in both P450 and in other haem containing proteins when animals are treated with CIM ([Baird *et al*, 1987](#bib1){ref-type="other"}).

Since elucidation of a specific form of microsomal P450 exclusively associated with azoreduction remains elusive ([Zbaida, 1995](#bib35){ref-type="other"}), we have shown that administration of DAB to mice, remarkably increases total P450 and that these changes are associated with hepatoxicity and lipid peroxidation, leading to the carcinogenesis onset. Considering that in our experimental model, the sustained P450 induction provoked as a consequence of the carcinogen metabolism, is responsible for the liver injury and the peroxidative damage, our aim was to investigate if diminution of P450 caused by CIM could avoid the biochemical aberrations associated with the initiation stage of hepatocarcinogenesis ([Gerez *et al*, 1998a](#bib11){ref-type="other"},[b](#bib12){ref-type="other"}; [Caballero *et al*, 2001](#bib2){ref-type="other"}).

MATERIALS AND METHODS
=====================

Chemicals
---------

Chemicals were reagent grade and purchased from Sigma Chemical Co. (St. Louis, MO, USA).

Animals and treatment
---------------------

Male *CF1* mice (30 g) received a standard laboratory diet (SLD, Purina 3, Asociación de Cooperativas Argentinas, San Nicolás, Buenos Aires) (groups A, *n*=16) or were placed on dietary p-dimethylaminoazobenzene (DAB, 0.5%, w/w) (groups B, *n*=16). After 40 days, animals of both groups (A and B) received DAB and two weekly doses of CIM (120 mg kg^−1^ i.p.) (A~CIM~; B~CIM~) or saline (A~S~, B~S~) for a following period of 35 days ([Mera *et al*, 1994](#bib22){ref-type="other"}). Other group (CIM) of animals (*n*=6) received SLD along the whole period of assay and were injected with CIM under the same scheduled protocol than the DAB treated groups. Animals of control group (*n*=6) were fed with the SLD and received saline i.p. twice a week for the same period. The treatment protocol is shown in [Figure 1](#fig1){ref-type="fig"}Figure 1Experimental design. . All animals were given food and water *ad libitum*.

All animals were inspected at least twice daily. Body weight and food consumption were measured at intervals throughout the study. Food was removed from animals 16 h before sacrifice. Mice were killed (at least six animals per group) under ether anaesthesia at the indicated times and liver samples were processed immediately as previously described ([Gerez *et al*, 1998a](#bib11){ref-type="other"}). All animals received human care and were treated in accordance with guidelines established by the Animal Care and Use Committee of the Argentine Association of Specialists in Laboratory Animals (AADEALC) and in accordance with the UK Guidelines for the Welfare of Animals in Experimental Neoplasia ([UKCCCR, 1998](#bib30){ref-type="other"}).

Assays
------

δ-Aminolevulinic acid synthetase (ALA-S) activity was measured as described by [Marver *et al* (1966)](#bib21){ref-type="other"} and microsomal haem oxygenase (HO) activity according to [Yoshida and Kikuchi (1978)](#bib34){ref-type="other"}.

Cytochrome P450 (P450) content was determined in the microsomal fraction according to [Omura and Sato (1964)](#bib25){ref-type="other"}. Glutathione S transferase (GST) was determined by the method of [Habig *et al* (1974)](#bib13){ref-type="other"}. Catalase was measured as described by [Chance and Maehly (1955)](#bib4){ref-type="other"}.

The lipid peroxidation (LP) index was evaluated by the formation of malondialdehyde and determined as thiobarbituric acid reactive species (TBARS) by the method of [Niehaus and Samuelson (1968)](#bib24){ref-type="other"}. Protein concentration was determined by the method of [Lowry *et al* (1951)](#bib18){ref-type="other"}. Enzyme units (U) were defined as the amount of enzyme producing 1 nmol of product or consuming 1 nmol of substrate (catalase) under the standard incubation conditions. Specific activity (Sp. Act.) was expressed as U mg^−1^ protein.

Statistical analysis
--------------------

Newman-Keuls test was used to assess the degree of significance. A probability level of 0.05 was used in testing for significant differences between controls and treated animals.

RESULTS
=======

As already shown, DAB induced a significant increase in P450 content ([Gerez *et al*, 1997](#bib10){ref-type="other"}) and as expected CIM provoked 40% reduction in P450 levels ([Nanji *et al*, 1994](#bib23){ref-type="other"}). Simultaneous administration of CIM and DAB (A~CIM~) partially prevented the enhancement of P450 content. When animals were pre-treated with DAB and then received CIM (B~CIM~) induction of P450 was also partially reversed. In both cases, after CIM treatment P450 levels were still 50% above basal levels ( [Figure 2](#fig2){ref-type="fig"}Figure 2Effect of CIM on hepatic P450 levels. Animals were treated under the experimental protocol, described in [Figure 1](#fig1){ref-type="fig"}. Open bar CIM, hatched bars Treatment groups A, solid bars Treatment groups B. The data represent mean values±s.d. and are expressed as percentage of the corresponding mean control values of SLD fed animals without any other treatment, for each time point. Saline control group (mean±s.d.): P450=0.34±0.03 nmol mg^−1^ protein. Significantly different (*P*\<0.05) from saline treated group \* and the corresponding DAB group (A~S~ or B~S~) \*\*. ).

It has already been reported that CIM could reduce the activity of hepatic ALA-S induced by allylisopropylacetamide (AIA) in porphyric adult rats ([Marcus *et al*, 1990](#bib20){ref-type="other"}) and that CIM could also be used in the prophylaxis of human acute intermittent porphyria by maintaining a baseline suppression of ALA-S activity ([Horie *et al*, 1995](#bib15){ref-type="other"}; [Rogers, 1997](#bib28){ref-type="other"}). In this study, CIM itself inhibited 40% ALA-S activity. CIM also prevented ALA-S induction provoked by DAB restoring basal levels at the end of the treatment (A~CIM~) and even partially reversed this induction in animals pre-treated with DAB (B~CIM~), achieving a 43% diminution respect to the B~S~ group ( [Figure 3a](#fig3){ref-type="fig"}Figure 3Effect of CIM on hepatic ALA-S (**A**) and HO (**B**) activities. Saline control group (mean±s.d.): ALA-S=1.4×10^−4^±0.3×10^−4^ U mg^−1^ protein; HO=2.25±0.11 U mg^−1^ protein. Other experimental conditions and symbols are as indicated in Materials and Methods and legends to [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. Significantly different (*P*\<0.05) from saline treated group \* and the corresponding DAB group (A~S~ or B~S~) \*\*. ).

CIM was found to inhibit both *in vivo* and *in vitro* the rate limiting enzymes of haem degradation, and it was suggested that the drug itself or a metabolite would inhibit HO ([Marcus *et al*, 1984](#bib19){ref-type="other"}). In our experimental system, CIM given alone inhibited 25% HO activity and no effect was detected on the reduction of HO activity already provoked by DAB ([Figure 3b](#fig3){ref-type="fig"}).

Catalase is a haem protein present in high concentration in mammalian liver. Although administration of CIM to mice affects the synthesis and degradation of haem, no alteration in catalase activity had been described so far ([Baird *et al*, 1987](#bib1){ref-type="other"}). In this study, CIM did not modify catalase activity in either controls or in DAB treated animals. Instead, as previously reported ([Caballero *et al*, 2001](#bib2){ref-type="other"}) a significant inhibition has been observed in animals receiving only the carcinogen (A~S~: 50%; B~S~: 74%) ( [Figure 4a](#fig4){ref-type="fig"}Figure 4Effect of CIM on hepatic catalase activity (**A**) and LP (TBARS content, **B**). Saline control group (mean±s.d.): TBARS=135×10^−3^± 24×10^−3^ nmol mg^−1^ protein; Catalase=1.9×10^3^±0.2×10^3^ U mg^−1^ protein. Other experimental conditions and symbols are as indicated in Materials and Methods and legends to [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. Significantly different (*P*\<0.05) from \* saline treated group and the \*\* corresponding DAB group (A~S~ or B~S~) . ).

It was demonstrated that CIM could not prevent CCl~4~-induced LP *in vivo* ([Cluet *et al*, 1986](#bib7){ref-type="other"}). [Johnston and Kroening (1998)](#bib16){ref-type="other"} have observed that CIM inhibited LP in primary rats hepatocytes in culture but it did not reduce hepatocyte death induced by CCl~4~. We have found here that CIM alone did not produce any alteration in the LP index. Co-treatment (DAB+CIM) did not modify increased LP produced by DAB (A~CIM~: 110%; B~CIM~: 220%) ([Figure 4b](#fig4){ref-type="fig"}).

As expected CIM produced only 25% increase in GST activity. The significant enhancement (110%) in GST activity provoked by DAB ([Gerez *et al*, 1998b](#bib12){ref-type="other"}) persisted in those animals also receiving CIM ( [Figure 5](#fig5){ref-type="fig"}Figure 5Effect of CIM on hepatic GST activity. The data represent mean values±s.d. and are expressed as percentage of the corresponding mean control values of SLD fed animals without any other treatment, for each time point. Saline control group (mean±s.d.): GST=1.45±0.25 U mg^−1^ protein. Other experimental conditions and symbols are as indicated in Materials and Methods and legends to [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}. Significantly different (*P*\<0.05) from \* saline treated group and the \*\* corresponding DAB group (A~S~ or B~S~). ).

DISCUSSION
==========

CIM a substituted imidazole, has been well documented to inhibit hepatic P450 mediated drug metabolism in rats and humans ([Chang *et al*, 1992b](#bib6){ref-type="other"}). Numerous drug-drug interactions involving CIM have been identified, in most cases, due to inhibition of hepatic drug metabolism by CIM occurring at very low serum concentrations ([Chang *et al*, 1992b](#bib6){ref-type="other"}). *In vitro* addition of CIM to hepatic microsomes has been shown to inhibit the P450 catalysed oxidation of many substrates, considering CIM as a general inhibitor of P450 enzymes, although [Reilly *et al* (1988)](#bib27){ref-type="other"} have suggested that there is in fact a more selective action for CIM. It was also proposed, that the varying effects of CIM on P450 enzymes could be attributed to different CIM binding affinities for these mixed function oxidases ([Faux and Combes, 1993](#bib8){ref-type="other"}). The inhibitory effect of CIM on the metabolic activity of CYP2C9, 2C19, 2D6 y 3A was recently demonstrated in human liver microsomes ([Furuta *et al*, 2001](#bib9){ref-type="other"}).

P450 induction is important in the pathogenesis of alcoholic hepatic diseases and it has been demonstrated that CIM can prevent alcoholic hepatic injury by reducing LP ([Nanji *et al*, 1994](#bib23){ref-type="other"}). [Mera *et al* (1994)](#bib22){ref-type="other"} have also investigated whether CIM might prevent CCl~4~ induced liver cirrhosis by preventing the increase in hepatic collagen content and/or LP. They did found a protective effect of CIM, which was attributed to a reduction in P450. They have also observed that CIM stimulated the regenerative process.

Quantitative ultrastructural studies of CIM treated rat liver showed a significant proliferation of smooth endoplasmic reticulum, changes which were qualitatively similar to those produced by phenobarbital ([Wright *et al*, 1991](#bib32){ref-type="other"}).

We have demonstrated here that CIM partially prevented and reversed the induction of P450 levels produced by the carcinogenic agent DAB. Because DAB metabolism through the mono-oxygenase system is responsible for liver damage, decrease in P450 could ameliorate or delay this process ([Yan *et al*, 1998](#bib33){ref-type="other"}). However, the significant increase in GST activity provoked by DAB still persisted in animals also receiving CIM, indicating that reduction in P450 by CIM is not enough to completely overcome DAB toxicity and suggesting that other mechanisms would be participating in the whole process.

CIM restored ALA-S basal levels induced by DAB, but it did not reverse HO inhibition. If administration of CIM to mice would affect haem synthesis, changes in the activity of any haem protein such as catalase, would be expected. However, we did not observe any changes in either DAB treated or control animals. It has been previously demonstrated that neither acute nor chronic treatment of mice with CIM produced any effect on catalase or had any action on haem metabolism, or it did interact with any haem containing protein ([Baird *et al*, 1987](#bib1){ref-type="other"}). Thus, both our evidence and that of others is consistent with the hypothesis proposing that CIM alters the metabolism of some compounds through its specific interaction with P450.

Therefore, as a result of DAB metabolism, ROS and reactive nitrogen species (RNS) are generated. Free radicals induced LP and the role of free radicals in carcinogenesis is also well known ([Cerutti, 1994](#bib3){ref-type="other"}). LP index, greatly enhanced in animals fed with DAB, was not modified by CIM, consequently liver cytotoxicity should be ascribed to oxidative stress and it was here demonstrated by the persistent increase in GST activity.

We have also shown that free radicals excess was not modified by CIM in animals subjected to the carcinogenic diet, and as a consequence catalase inhibition was not affected by co-treatment of DAB and CIM. This irreversible autocatalytic process produces then a continuous increase in ROS and RNS generation leading to a desbalance between radicals and the antioxidant defence system ([Pigeolet *et al*, 1990](#bib26){ref-type="other"}).

It is noteworthy, that increased GST, diminished catalase, and enhanced LP reflecting initiation of carcinogenesis ([Gerez *et al*, 1998a](#bib11){ref-type="other"},[b](#bib12){ref-type="other"}; [Caballero *et al*, 2001](#bib2){ref-type="other"}), were not modified by CIM, in spite of its partial reversal in the increased P450 levels.

These results further support our hypothesis about the necessary multiple biochemical pathway disturbances for the onset of hepatocarcinogenesis initiation ( [Figure 6](#fig6){ref-type="fig"}Figure 6Proposed mechanism for the initiation stage of chemical induced carcinogenesis. ).

These findings also provide evidence for the importance of animal experiments in studying the multiple action and crosstalk among different biochemical pathways provoked by the administration of xenobiotics.
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